-
At Long Last, Dynavax Wins FDA Approval For Heplisav
Friday, November 10, 2017 - 9:44am | 402Read More...Dynavax Technologies Corporation (NASDAQ: DVAX), a clinical-stage immunotherapy company, confirmed on Thursday the U.S. Food and Drug Administration approved its two-dose vaccine The company failed to gain approval for its therapy in February 2013 and in November 2016. But now that the...
-
Dynavax Awaits FDA Verdict On Hepatitis B Vaccine
Wednesday, November 8, 2017 - 4:04pm | 705Read More...Undaunted by two earlier FDA snubs, Dynavax Technologies Corporation (NASDAQ: DVAX) is trying again with its hepatitis B vaccine, Heplisav. Will it successfully scale the hurdle the third time? Investors are waiting for an answer, as the FDA is set to give its verdict on the Biologic License...
-
Oppenheimer's Current Biotech Ratings
Monday, September 13, 2010 - 10:41am | 138Read More...Stock Prices as of September 10, 2010 Anadys Pharmaceuticals Inc. (NASDAQ: ANDS) $1.75, PERFORM BioMarin Pharmaceutical (NASDAQ: BMRN) $22.62, PERFORM Chelsea Therapeutics (NASDAQ: CHTP) $3.91, PERFORM Dynavax Technologies (NASDAQ: DVAX) $1.69, PERFORM Genzyme (NASDAQ: GENZ) $70.63, PERFORM...
